Steven Valiquette
Stock Analyst at Mizuho
(3.53)
# 883
Out of 5,140 analysts
120
Total ratings
55.38%
Success rate
5.05%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Maintains: Neutral | $74 → $81 | $77.73 | +4.21% | 6 | Jan 20, 2026 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $13 → $14 | $12.05 | +16.18% | 8 | Jan 20, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $200 | $165.55 | +20.81% | 13 | Jan 20, 2026 | |
| NVST Envista Holdings | Upgrades: Neutral | $19 → $24 | $24.34 | -1.40% | 3 | Jan 20, 2026 | |
| SOLV Solventum | Upgrades: Outperform | $85 → $100 | $78.96 | +26.65% | 3 | Jan 20, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $44.15 | +8.72% | 1 | Jan 12, 2026 | |
| PHR Phreesia | Maintains: Outperform | $36 → $28 | $15.73 | +78.00% | 2 | Dec 10, 2025 | |
| LFMD LifeMD | Maintains: Neutral | $8 → $6 | $3.56 | +68.54% | 2 | Nov 19, 2025 | |
| GDRX GoodRx Holdings | Maintains: Neutral | $5 → $4 | $2.60 | +53.85% | 1 | Nov 6, 2025 | |
| COR Cencora | Maintains: Outperform | $340 → $380 | $350.67 | +8.36% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $210 | $210.37 | -0.18% | 7 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $29.74 | +68.12% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $750 → $770 | $821.84 | -6.31% | 4 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $295 → $325 | $216.26 | +50.28% | 4 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $6.07 | +64.74% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $60 | $41.10 | +45.99% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $84.00 | +50.00% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.77 | +32.63% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $199.87 | -28.95% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $78.18 | -29.65% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $188.00 | -51.06% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $338.43 | +66.95% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $80.09 | +24.86% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $5.14 | +172.37% | 1 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $191.27 | +109.13% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $45.76 | +133.83% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $37.35 | -54.48% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $12.10 | -0.83% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $98.83 | -2.86% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $188.95 | -36.49% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $464.38 | -72.65% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $268.00 | +33.58% | 3 | Dec 6, 2019 |
Henry Schein
Jan 20, 2026
Maintains: Neutral
Price Target: $74 → $81
Current: $77.73
Upside: +4.21%
DENTSPLY SIRONA
Jan 20, 2026
Maintains: Neutral
Price Target: $13 → $14
Current: $12.05
Upside: +16.18%
Align Technology
Jan 20, 2026
Maintains: Outperform
Price Target: $170 → $200
Current: $165.55
Upside: +20.81%
Envista Holdings
Jan 20, 2026
Upgrades: Neutral
Price Target: $19 → $24
Current: $24.34
Upside: -1.40%
Solventum
Jan 20, 2026
Upgrades: Outperform
Price Target: $85 → $100
Current: $78.96
Upside: +26.65%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $44.15
Upside: +8.72%
Phreesia
Dec 10, 2025
Maintains: Outperform
Price Target: $36 → $28
Current: $15.73
Upside: +78.00%
LifeMD
Nov 19, 2025
Maintains: Neutral
Price Target: $8 → $6
Current: $3.56
Upside: +68.54%
GoodRx Holdings
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $2.60
Upside: +53.85%
Cencora
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $350.67
Upside: +8.36%
Nov 4, 2025
Maintains: Outperform
Price Target: $170 → $210
Current: $210.37
Upside: -0.18%
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $29.74
Upside: +68.12%
Sep 24, 2025
Maintains: Neutral
Price Target: $750 → $770
Current: $821.84
Upside: -6.31%
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $216.26
Upside: +50.28%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $6.07
Upside: +64.74%
May 16, 2025
Maintains: Neutral
Price Target: $65 → $60
Current: $41.10
Upside: +45.99%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $84.00
Upside: +50.00%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $3.77
Upside: +32.63%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $199.87
Upside: -28.95%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $78.18
Upside: -29.65%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $188.00
Upside: -51.06%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $338.43
Upside: +66.95%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $80.09
Upside: +24.86%
Feb 27, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $5.14
Upside: +172.37%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $191.27
Upside: +109.13%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $45.76
Upside: +133.83%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $37.35
Upside: -54.48%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $12.10
Upside: -0.83%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $98.83
Upside: -2.86%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $188.95
Upside: -36.49%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $464.38
Upside: -72.65%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $268.00
Upside: +33.58%